(Q33360471)

26 July 2017

Performing meta-analysis with incomplete statistical information in clinical trials (English)

1 reference

26 July 2017

0 references

1 reference

Jianbing Ma

1

0 references

Weiya Zhang

object named as

Weiya Zhang

series ordinal

4

0 references

author name string

Weiru Liu

series ordinal

2

1 reference

PubMed ID

18706124

26 July 2017

Anthony Hunter

series ordinal

3

1 reference

26 July 2017

18 August 2008

1 reference

BMC Medical Research Methodology

26 July 2017

1 reference

26 July 2017

8

1 reference

26 July 2017

56

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

start time

18 August 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2288-8-56

0 references

cites work

Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Uncertainty method improved on best-worst case analysis in a binary meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Effects of metformin and glibenclamide alone and in combination on serum lipids and lipoproteins in patients with non-insulin-dependent diabetes mellitus.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Comparing bimatoprost and travoprost in black Americans

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-8-56

Axial length of the ocular globe and hypotensive effect in glaucoma therapy with prostaglandin analogs

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Comparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design study.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2571096

Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18706124

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparison of two fixed combinations of latanoprost and timolol in open-angle glaucoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18706124

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2288-8-56

1 reference

PubMed ID

18706124

Dimensions Publication ID

26 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2288-8-56

9 September 2019

1 reference

26 July 2017

1 reference

PubMed ID

18706124